Tenaya Therapeutics Stock

tenayatherapeutics.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $142MM

Tenaya Therapeutics is a biopharmaceutical company focused on addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration.

Register To Buy and Sell Shares

For more details on financing and valuation for Tenaya Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Tenaya Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Tenaya Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

JJ Kang Ph.D
President & Board Member
Benoit Bruneau Ph.D
Scientific Co-Founder
Sheng Ding Ph.D
Co-Founder
Timothy Hoey Ph.D
Chief Scientific Officer
Bruce Conklin MD
Scientific Co-Founder
Whittemore Tingley Ph.D
Chief Medical Officer
Faraz Ali
Board Member & Chief Executive Officer
Deepak Srivastava MD
Scientific Co-Founder & Board Member
Saptarsi Haldar MD
Scientific Co-Founder
Eric Olson Ph.D
Scientific Co-Founder

Board Members

David Goeddel Ph.D
The Column Group
Jin-Long Chen Ph.D
Deepak Srivastava MD
Faraz Ali
JJ Kang Ph.D
Anthony Philippakis MD
GV
Eli Casdin
Casdin Capital
Robert Sanders Williams MD

News Highlights

Tenaya Therapeutics Raises $92 Million In Funding To Deliver Curative Heart Disease Therapies
Tenaya Therapeutics, a company aiming to discover and develop curative therapies that target the underlying causes of heart disease, has raised $92 million.
Tenaya Therapeutics Closes $92 Million Series B Financing
/PRNewswire/ -- Tenaya Therapeutics, Inc., a company with a mission to discover, develop, and deliver curative therapies that target the underlying causes of...
Updated on: May 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.